Contribute Try STAT+ Today

Editor’s note: The archived video is embedded below.

The health tech industry has become a crucial player — and faces a key test — amid the coronavirus pandemic. Telehealth providers are seeing a sudden, explosive uptick in interest for their services. Hospitals across the country are turning to artificial intelligence tools. Tech giants and small startups alike have launched efforts to not only screen and diagnose patients, but also to study the virus itself and better predict its spread. Meanwhile, much of the industry’s regular activity — from funding rounds to product launches — has come screeching to a halt as companies pause projects and throw their resources into the pandemic response.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.